Product Description
GSK-163090 is potent, selective, and orally active 5-HT1A/B/D receptor antagonist. GSK163090 was found to combine potent in vivo activity with a strong preclinical developability profile, and on this basis it was selected as a drug candidate with the aim of assessing its potential as a fast-onset antidepressant/anxiolytic. GSK-163090 had been in phase II clinical trials by GlaxoSmithKline for the treatment of major depressive disorder (MDD) and anxiety disorders.Ê (Sourced from: https://drugs.ncats.io/drug/7XI927X82B)
Mechanisms of Action: 5-HT1A Antagonist,5-HT1B Antagonist,5-HT1D Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Depressive Disorder, Major
Phase 1: Depressive Disorder|Depressive Disorder, Major
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT00896363 | P2 |
Completed |
Depressive Disorder, Major |
2010-02-09 |
|
HTP110333 | P1 |
Completed |
Depressive Disorder, Major |
2008-06-01 |
|
HTP103265 | P1 |
Completed |
Depressive Disorder |
2007-12-01 |
|
NCT00536679 | P1 |
Completed |
Depressive Disorder |
2007-11-05 |